Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;243(17-18):1323-1330.
doi: 10.1177/1535370218817746. Epub 2018 Dec 12.

Intermittent blockade of OGFr and treatment of autoimmune disorders

Ian S Zagon  1 , Patricia J McLaughlin  1
Affiliations
Review

Intermittent blockade of OGFr and treatment of autoimmune disorders

Ian S Zagon et al. Exp Biol Med (Maywood). 2018 Dec.

Abstract

This mini-review presents information on the intermittent blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) axis by low-dose naltrexone (LDN), and the role of enkephalin (i.e. OGF) in autoimmune disorders, specifically multiple sclerosis, Crohn's, and fibromyalgia. Clinical reports on subjects taking LDN have documented reduced fatigue, few side-effects, and improved overall health. Preclinical studies on mice with experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis, revealed that immunization for EAE reduces serum OGF. Intermittent OGFr blockade with LDN restores serum enkephalin levels that correlate with reduced behavioral and pathological signs of EAE; LDN also increases enkephalin levels in naïve mice. The interplay between LDN, and the onset and treatment of autoimmune diseases, chronic pain, and other addictive behaviors requires further investigation, but highlights a central role for enkephalins and intermittent blockade of the OGF-OGFr pathway in pathogenesis and treatment of these disorders.

Keywords: Enkephalin; fibromyalgia; low-dose naltrexone; multiple sclerosis; opioid growth factor; opioid growth factor receptor.

PubMed Disclaimer

References

    1. Hughes J, Smith TW, Kosterlitz HW, Fothergill LH, Morgan BA, Morris HR. Identification of two pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258:577–9 - PubMed
    1. Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 1975; 88:295–308 - PubMed
    1. Pert CB, Snyder SH. Opiate receptor demonstration in nervous tissue. Science 1973; 179:1011–4 - PubMed
    1. Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic [3H]-etorphine to rat-brain homogenate. Proc Natl Acad Sci U S A 1973; 70:1947–9 - PMC - PubMed
    1. Zagon IS, Goodman SR, McLaughlin PJ. Characterization of opioid binding sites in murine neuroblastoma. Brain Res 1988; 449:80–8 - PubMed

Publication types

MeSH terms